Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 5, Mai 2008
Page(s) 459 - 462
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2008245459
Publié en ligne 15 mai 2008
  1. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7 : 475–85.
  2. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358 : 95–7.
  3. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131 : 463–75.
  4. Luttun, A, Tjwa M, Moons L, et al. 2002. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8 : 831–40.
  5. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7 : 575–83.
  6. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy : continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23 : 8136–9.
  7. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 : 16–24.
  8. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9 : 936–43.
  9. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65 : 550–63.
  10. Kulke MH. Neuroendocrine tumours : clinical presentation and management of localized disease. Cancer Treat Rev 2003; 29 : 363–70.
  11. Ratain MJ. Phase II oncology trials : let’s be positive. Clin Cancer Res 2005; 11 : 5661–2.
  12. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6 : 734–45.
  13. Behar-Cohen F, Sennlaub F, Berdugo M. Espoirs thérapeutiques dans la dégénérescence maculaire liée à l’âge. Med Sci (Paris) 2007; 23 : 127–9.
  14. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87 : 161–7.
  15. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005; 23 : 2831–9.
  16. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20 : 4434–9.
  17. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17 : 961–7.
  18. Blay JY. Le futur des thérapeutiques ciblées en oncologie, trouver les cibles, traiter tôt et au long cours. Med Sci (Paris) 2008; 23 : 1073–4.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.